HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Indian Court Nixes Bayer's Nexavar Patent Plea; Cipla Allowed To Market Generic Versions

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In a landmark decision that will further restrict multinational drug companies from introducing their internationally marketed brands in India, the Delhi High Court rejected German drug maker Bayer's plea to stop the Drug Controller General of India - the Indian drug regulator - from granting marketing approval to generic drug maker Cipla for kidney/liver cancer drug Nexavar (sorafenib)

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
Scrip
Tags:
Latest Headlines

Walmart Lays Out Expectations For Beauty Brands' MoCRA Compliance

US Consumer Health Market People News: Herbalife, Seed Health, Electrolit, Atlas Bars, More

US Women’s Health Sector: Hip Hop Stars Invest In Proov, Good Clean Love Names CEO

Reckitt Sees R&D Investment Translate To Volume Growth

See All
UsernamePublicRestriction

Register

SC072520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By